# Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

> **NCT00661492** · PHASE2 · COMPLETED · sponsor: **US Oncology Research** · enrollment: 115 (actual)

## Conditions studied

- Androgen-independent Prostate Cancer

## Interventions

- **DRUG:** cetuximab
- **DRUG:** Mitoxantrone

## Key facts

- **NCT ID:** NCT00661492
- **Lead sponsor:** US Oncology Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2011-03
- **Final completion:** 2011-06
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2016-12-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661492, "Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00661492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*